News

On 10 June 2016 ,Maciej Wieczorek, PhD, CEO of Celon Pharma S.A. presented potential ares of cooperation between young scientists and Celon Pharma’s Research and Development Centre. In a short presentation of the company, Maciej Wieczorek encouraged young people to take up research initiatives in cooperation with Polish pharmaceutical companies. Cooperation with the scientific communityRead more »

The objective of the project is to confirm the therapeutic action of the PI3K inhibitor in patients with lung diseases such as asthma or chronic obstructive pulmonary disease (COPD). The planned route of administration of the drug is inhalation. The project involves actions taken in four stages, including preclinical and toxicological studies, drug formulation, asRead more »

Leaders of research groups from the Celon Pharma S.A. Research and Development Centre provided information on current innovative projects run by the company at an exhibition stand prepared specially for the event. Additionally, on 9 May Maciej Wieczorek, PhD, CEO of Celon Pharma S.A. took part in a panel discussion which brought together guests fromRead more »

Does working in a bank teach you discipline? What was the Polish pharmaceutical sector like in the 1990s and what is the entrepreneurial ethos? Maciej Wieczorek was a guest on a show called Twarze Biznesu (The Faces of Business) hosted by Michał Broniatowski. We encourage you to watch the entire video.   http://biznes.onet.pl/wiadomosci/medycyna/twarze-biznesu-lek-na-raka-od-polskiego-milionera/drx6dj

On 9 and 10 May 2016 Celon Pharma S.A. representatives will participate in this year’s edition of BioForum, the most important event in biotechnology in Poland. This year BioForum will be held in the city of Lodz. For the fifteenth time the event will bring together representatives of business and science associated with the broadlyRead more »

The Second International Congress of Forensic Psychiatry took place on 15-16 April 2016. The “Aurelius Awards” were conferred during the event. The initiative was supported by Celon Pharma S.A. The aim of the “Aurelius Awards” is to recognise individuals who work to improve the quality of life of the mentally ill and who introduce aRead more »

On 30 March this year the inaugural meeting was held for the research project: Development of modern biomarkers and development of an innovative FGFR kinase inhibitor for the treatment of neoplastic diseases – CELONKO; the meeting offered the project participants the chance to learn the main assumptions and current status of the project.

On 18 March Celon Pharma S.A. hosted another meeting of “InnoNeuroMed”, the Polish Innovative Neuromedicine Platform. The theme of the meeting was: different aspects of affective disorders. The meeting was attended by members of the Platform representing leading scientific institutions and pharmaceutical companies working in the field of neuromedicine in Poland.

    The project entitled “New S-ketamine therapy for treatment-resistant depression” aims to develop a technology for a new route of ketamine administration in patients suffering from severe forms of treatment-resistant depression. Katamine is a well-known and widely used general anaesthetic. Recently, the possibility of its use in treatment of severe episodes of treatment-resistant depressionRead more »

Celon Pharma S.A. signed an agreement with Glemnark Pharmaceutical Europe Limited on commercialisation of Salmex into several European countries. The company concluded an agreement under which it undertakes to, inter alia, supply a pharmaceutical product approved for marketing in selected European markets. The distribution agreement was concluded for a period of 10 years, with anRead more »